Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Precigen Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 distinct examiners across 4 distinct art units, showing broad examiner distribution with some art-unit concentration.
ALLEN, MICHAEL D is the busiest examiner, with 1 pending office action. Because no examiner carries more than the listed amount, counsel should emphasize matter-specific analysis while using art-unit groupings to identify recurring substantive issues.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
| QIAN, CELINE X | 1 | 47.5% | +17.2% |
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
| LY, KRISTINA ELISABETH | 1 | 37.5% | +100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259985 | Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof | QIAN, CELINE X | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18671275 | HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME | ALLEN, MICHAEL D | — |
| 18259985 | Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof | QIAN, CELINE X | — |
| 18344421 | POLYPEPTIDE COMPOSITIONS COMPRISING SPACERS | OUSPENSKI, ILIA I | — |
| 18253624 | Human Papilloma Virus Vaccines and Uses of the Same for HPV Associated Diseases | LY, KRISTINA ELISABETH | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| 1637 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18671275 | HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME | ALLEN, MICHAEL D | 1671 | §103§112DP | Non-Final OA | — | Pending | May 22, 2024 |
| 18259985 | Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof | QIAN, CELINE X | 1637 | §103§112 | Non-Final OA | — | Pending | Jun 29, 2023 |
| 18344421 | POLYPEPTIDE COMPOSITIONS COMPRISING SPACERS | OUSPENSKI, ILIA I | 1644 | §102§112DP | Final Rejection | — | Pending | Jun 29, 2023 |
| 18253624 | Human Papilloma Virus Vaccines and Uses of the Same for HPV Associated Diseases | LY, KRISTINA ELISABETH | 1671 | §103 | Final Rejection | — | Pending | May 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPrecigen Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Michael D Allen has the most, with 1 of Precigen Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
